Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 17Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 11Leukemia, Megakaryoblastic, Acute 11Leukemia, Erythroblastic, Acute 11Breast Neoplasms 11Congenital Abnormalities 9Leukemia 7Glioblastoma 7Recurrence 6Pancreatic Neoplasms 6Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Anemia, Refractory, with Excess of Blasts 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Breast Neoplasms, Male 4Brain Neoplasms 4Blast Crisis 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Melanoma 3

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Geriatric Assessment 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Neoplasm × tipifarnib × Clear all
NCT00085553 2018-05-18

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡